| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 1x16h,1x2hor2x2h |
| Standardrange | 60-820ng/mL |
| Specimen/Volumes | 20µLSerum,Plasma |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | EU:CE |
ThenewChromograninAELISAshowshighclinicalspecificityandsensitivityforthedifferentneuroendocrinetumors(NET)duetomonoclonalantibodiesdirectedagainstthecentralpartofmolecule,whichcorrespondstotheunprocessedcentraldomain.
Originandmetabolism
ChromograninA(CgA)isthoughttoactasapro-hormone.Itsproteolysisisakeycomponentofitsphysiology.ThisdegradationreleasesBIOLOGicallyactivepeptides(vasostatins,chromostatin,pancreastatin,parastatin),whichpossessdifferentparacrineandautocrinefunctions.ThesepeptidesarenotspecifictoNET-patients.Thisproteolysisistissue-specificandfragmentationoftheproteinisdifferentdependingonitslocation.Itprimarilytakesplaceinthecell,insidechromaffingranules.Inimmunohistochemistry,thepresenceofCgAintumorcellsissuggestiveofaneuroendocrineoriginofthetumor.
HumanCGAmoleculesequence
ThenewELISAusesmonoclonalantibodiesthatspecificallyrecognizethecentralpartofthemolecule(145-245),whichcorrespondstotheunprocessedcentraldomain.ThekitmeasuresintactandfragmentedcirculatingCgA.
Thisdesigniskeyfor:
- HighclinicalspecificityforNETpatients
- Reliableandconsistentresults:standardsbasedonhumanrecombinantCgA
- Highprecision<10%CV%
- ExcellentcorrelationtothegoldStandardCgARIAandtotheKryptorassay
Precision
| Samples | n | Concentration Mean(ng/mL) | Within-series (CV%) |
| 1 | 35 | 24.3 | 6 |
| 2 | 35 | 92 | 5 |
| 3 | 35 | 374 | 4 |
| 4 | 35 | 677 | 4 |
| Samples | n | Concentration Mean(ng/mL) | Between-series (CV%) |
| 5 | 13 | 50.2 | 10 |
| 6 | 13 | 119 | 8 |
| 7 | 13 | 303 | 6 |
| 8 | 13 | 574 | 5 |
| Samples | n | Concentration Mean(ng/mL) | Within-series (CV%) |
| 9 | 35 | 29.2 | 5 |
| 10 | 35 | 94 | 5 |
| 11 | 35 | 313 | 4 |
| 12 | 35 | 501 | 6 |
| Samples | n | Concentration Mean(ng/mL) | Between-series (CV%) |
| 13 | 11 | 38 | 12 |
| 14 | 9 | 103 | 6 |
| 15 | 11 | 198 | 6 |
| 16 | 9 | 460 | 4 |
Automation
TheChromograninAELISAcanbeeasilyautomatedonELISAopensystemslikeEvolyzer.Thecombineduseofassays,scriptandinstrumenthastobevalidatedindividuallyonsitebyeachlaboratory.
